Opus Genetics Operating Expenses 2010-2024 | IRD

Opus Genetics operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Opus Genetics Operating Expenses 2010-2024 | IRD

Opus Genetics operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$169.8B
Vertex Pharmaceuticals (VRTX)$121.4B
Gilead Sciences (GILD)$109.7B
Bristol Myers Squibb (BMY)$106.4B
Regeneron Pharmaceuticals (REGN)$102.2B
CSL (CSLLY)$92.8B
GSK (GSK)$79.1B
Alnylam Pharmaceuticals (ALNY)$36.5B
Argenex SE (ARGX)$33.1B
BioNTech SE (BNTX)$27.1B
Biogen (BIIB)$26.7B
Illumina (ILMN)$23.3B
Moderna (MRNA)$21.2B
BeiGene (BGNE)$21.1B
Genmab (GMAB)$15.3B
Incyte (INCY)$14.2B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$12.9B
Sarepta Therapeutics (SRPT)$12.4B
Insmed (INSM)$12.2B
Vaxcyte (PCVX)$11.8B
Bio-Techne Corp (TECH)$11.2B
QIAGEN (QGEN)$9.5B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.6B
Revolution Medicines (RVMD)$8.4B
Legend Biotech (LEGN)$8.3B
Exelixis (EXEL)$8.2B
Viking Therapeutics (VKTX)$8.2B
Intra-Cellular Therapies (ITCI)$8.1B